Cargando…
Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways
The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value‐based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical oncology...
Autor principal: | Hoverman, J. Russell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404003/ https://www.ncbi.nlm.nih.gov/pubmed/32524722 http://dx.doi.org/10.1002/cam4.3193 |
Ejemplares similares
-
Rethinking research into metastasis
por: Friedl, Peter
Publicado: (2019) -
Rethinking the role of clinical imaging
por: O'Connor, James PB
Publicado: (2017) -
Patient and physician opinion of virtual care in the oncology department of an Irish tertiary care centre in the era of Covid-19
por: O’Reilly, Mary, et al.
Publicado: (2021) -
Examining the association between oncology drug clinical benefit and the time to public reimbursement
por: Thomson, Sasha, et al.
Publicado: (2021) -
The added value of fasting blood glucose to serum squamous cell carcinoma antigen for predicting oncological outcomes in cervical cancer patients receiving neoadjuvant chemotherapy followed by radical hysterectomy
por: Wu, Miao‐Fang, et al.
Publicado: (2019)